Company Overview of Blueprint Medicines Corp.
Blueprint Medicines Corp., an oncology company, engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets. The company develops a platform that combines genomics with a novel library of kinase inhibitors to enable the development of highly selective compounds against clear genomic driver targets. Its products include KIT D816V, a validated driver mutation in aggressive systemic mastocytosis; isoform selective inhibitors of FGFR4; and programs against known and novel kinase fusions and resistance mutants. Blueprint Medicines Corp. has a strategic collaboration with Alexion. The company was incorporated in 2008 and is based in Cambrid...
215 First Street
Cambridge, MA 02142
Founded in 2008
Key Executives for Blueprint Medicines Corp.
Senior Vice President of Clinical Development
Compensation as of Fiscal Year 2014.
Blueprint Medicines Corp. Key Developments
Blueprint Medicines Announces Strategic Collaboration with Alexion to Advance Kinase Drug Candidates in Rare Genetic Disease
Mar 3 15
Blueprint Medicines announced a strategic collaboration with Alexion to discover, develop and commercialize novel drug candidates for an undisclosed activated kinase
target, which is the cause of a rare genetic disease. Blueprint Medicines will apply its kinase-focused drug discovery platform to identify and optimize drug candidates and will conduct all research activities prior to the filing of an Investigational New Drug (IND) application with the Food and Drug Administration. Alexion will be responsible for the development and commercialization of these Blueprint Medicines' drug candidates under the collaboration. Under the terms of the agreement, Blueprint Medicines will receive an upfront payment of $15 million and will be reimbursed for all research expenses. Blueprint Medicines is eligible to receive over $250 million in payments upon the successful achievement of pre-specified preclinical, clinical, regulatory and commercial milestones. In addition, Blueprint Medicines will be eligible to receive royalty payments following the commercialization of the product.
Blueprint Medicines Appoints Anthony (Andy) Boral as Senior Vice President, Clinical Development
Feb 11 15
Blueprint Medicines announced the appointment of Anthony (Andy) Boral, M.D., Ph.D., as Senior Vice President, Clinical Development. Dr. Boral joins Blueprint Medicines from Novartis Institutes for BioMedical Research, where he served for four years as Executive Director, Oncology Clinical Research. At Blueprint Medicines, he will join the executive management team and be responsible for clinical research and operations as well as regulatory affairs.
Dr. Boral brings more than 15 years of leadership in drug development. He also spent two years on staff in the Thoracic Oncology group at Massachusetts General Hospital.
Blueprint Medicines Corp. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 09:30 AM
Jan 8 15
Blueprint Medicines Corp. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 09:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Jeffrey W. Albers, Chief Executive Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 10, 2014